Genelux Co. (NASDAQ:GNLX) Receives $17.75 Average PT from Brokerages

Genelux Co. (NASDAQ:GNLX - Get Free Report) has earned a consensus rating of "Buy" from the five ratings firms that are currently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $17.75.

A number of equities analysts have recently weighed in on GNLX shares. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of Genelux in a research note on Monday, March 31st. Benchmark cut their price objective on Genelux from $25.00 to $23.00 and set a "speculative buy" rating on the stock in a research report on Thursday, May 8th. Finally, Wall Street Zen downgraded Genelux from a "hold" rating to a "sell" rating in a research note on Friday.

Institutional Investors Weigh In On Genelux

Several large investors have recently modified their holdings of GNLX. Apollon Wealth Management LLC lifted its stake in Genelux by 20.4% in the fourth quarter. Apollon Wealth Management LLC now owns 16,863 shares of the company's stock valued at $40,000 after purchasing an additional 2,857 shares during the last quarter. D.A. Davidson & CO. bought a new stake in shares of Genelux in the fourth quarter valued at $51,000. LifeSteps Financial Inc. lifted its position in shares of Genelux by 11.1% during the 4th quarter. LifeSteps Financial Inc. now owns 86,970 shares of the company's stock valued at $205,000 after buying an additional 8,715 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Genelux during the 4th quarter worth $41,000. Finally, Virtu Financial LLC bought a new position in shares of Genelux during the 4th quarter worth $25,000. Hedge funds and other institutional investors own 37.33% of the company's stock.

Genelux Stock Down 1.5%

NASDAQ GNLX traded down $0.04 on Friday, reaching $2.67. The company had a trading volume of 76,015 shares, compared to its average volume of 189,008. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89. The stock has a market capitalization of $100.75 million, a P/E ratio of -2.81 and a beta of -0.49. The company's fifty day moving average is $2.56 and its 200 day moving average is $3.07.

Genelux (NASDAQ:GNLX - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.03. On average, research analysts expect that Genelux will post -0.88 EPS for the current year.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.